It is currently trading at $5.62 which is well above the 50 day moving average which is $4.18 and which is quite a bit higher than the 200 day moving average of $2.04. The 50 day moving average went up $1.44 or +34.45% and the 200 day average moved up $3.58. Trading was light with 4,994 shares changing hands by the end of trading on Tuesday. Trading volume was down 95.91% under the stocks average daily volume.
Investors are more bearish on the company at least if you consider the uptick in short interest. The firm saw a rise in short interest from September 15, 2017 to September 29, 2017 of 103.99%. Short interest increased 1,146,855 over that period. Days to cover decreased -2.0 to 3.0 and the percentage of shorted shares was 0.11% on September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (CDNA). Gagnon Securities LLC grew its stake by buying 57,954 shares an increase of 2.9%. Gagnon Securities LLC now controls 2,084,292 shares worth $2,314,000. The value of the position overall is down by 18.4%. As of quarter end Blackrock Inc. had sold a total of 19,613 shares trimming its holdings by 86.0%. The value of the investment in CDNA decreased from $32,000 to $4,000 a change of $28,000 for the reporting period.
Tower Research Capital LLC (trc) reduced its ownership by selling 6,124 shares a decrease of 61.0% in the quarter. Tower Research Capital LLC (trc) currently owns 3,911 shares with a value of $4,000. The total value of its holdings decreased 71.4%. Gagnon Advisors, LLC augmented its investment by buying 1,808 shares an increase of 0.2% from 03/31/2017 to 06/30/2017. Gagnon Advisors, LLC controls 954,272 shares valued at $1,059,000. The total value of its holdings decreased 20.6%.
On September 27, 2017 the stock rating was changed to “Outperform” by Raymond James which is up from the previous “Market Perform” rating.
In the latest earnings report the EPS was $-1.39 and is projected to be $-0.82 for the current year with 22,541,000 shares now outstanding. Next quarter’s EPS is forecasted to be $-0.17 with next year’s EPS projected to be $-0.33.
CareDx, Inc., launched on December 21, 1998, is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Business’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap) is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. AlloMap is a non-invasive method recommended in the International Society for Heart and Lung Transplantation (ISHLT) patient care guidelines for surveillance of heart transplant rejection in patients 15 years of age or older..